📊 LUCD Key Takeaways
Is Lucid Diagnostics Inc. (LUCD) a Good Investment?
Lucid Diagnostics is a pre-commercial stage medical device company with severe cash burn dynamics that pose existential risk. With only $4.7M in annual revenue against -$46.7M operating cash outflow and ~$34.7M cash remaining, the company faces less than 12 months of runway. The 8% gross margin—critically weak for medical devices—combined with -$1,232.7% net margin reveals the company is far from viable operations.
Despite modest revenue growth, the company’s fundamentals show severely negative margins, massive cash burn, and poor returns on assets and equity, indicating unsustainable operations without additional financing. High leverage and negative interest coverage amplify solvency risk; until gross margin and operating leverage improve materially, downside risk dominates.
Why Buy Lucid Diagnostics Inc. Stock? LUCD Key Strengths
- Positive revenue growth of 8.3% YoY indicates market traction
- Holds $34.7M in cash providing near-term operational runway
- Operates in high-potential medical device sector with favorable regulatory environment
- Cash balance (~$34.7M) provides short-term liquidity runway
- Low capex needs support an asset-light model
- Some YoY improvement in net loss/EPS alongside revenue growth
LUCD Stock Risks: Lucid Diagnostics Inc. Investment Risks
- Approximately 9-month cash runway at -$46.7M annual operating cash burn rate; existential liquidity risk
- Gross margin of 8% is catastrophically low for medical devices; indicates fundamental business model challenges
- Debt-to-equity ratio of 2.22x creates refinancing pressure; negative interest coverage of -3,102.5x indicates inability to service debt from operations
- Severe cash burn and FCF deeply negative, raising dilution/going-concern risk
- High leverage (Debt/Equity 2.22x) with negative interest coverage
- Very low gross margin (8%) suggests weak unit economics and reimbursement/pricing pressure
Key Metrics to Watch
- Quarterly cash burn rate and estimated runway
- Revenue acceleration trajectory and gross margin expansion path
- Capital raise announcements and dilution impact on equity holders
- Gross margin expansion and COGS per test
- Quarterly operating cash burn and liquidity runway
Lucid Diagnostics Inc. (LUCD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Lucid Diagnostics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LUCD Profit Margin, ROE & Profitability Analysis
LUCD vs Healthcare Sector: How Lucid Diagnostics Inc. Compares
How Lucid Diagnostics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lucid Diagnostics Inc. Stock Overvalued? LUCD Valuation Analysis 2026
Based on fundamental analysis, Lucid Diagnostics Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lucid Diagnostics Inc. Balance Sheet: LUCD Debt, Cash & Liquidity
LUCD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lucid Diagnostics Inc.'s revenue has grown significantly by 769% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.26 indicates the company is currently unprofitable.
LUCD Revenue Growth, EPS Growth & YoY Performance
LUCD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.2M | -$10.4M | $-0.10 |
| Q2 2025 | $976.0K | -$4.4M | $-0.08 |
| Q1 2025 | $828.0K | -$10.6M | $-0.40 |
| Q3 2024 | $783.0K | -$12.4M | $-0.25 |
| Q2 2024 | $159.0K | -$11.0M | $-0.23 |
| Q1 2024 | $446.0K | -$10.6M | $-0.40 |
| Q3 2023 | $76.0K | -$14.2M | $-0.34 |
| Q2 2023 | $159.0K | -$11.4M | $-0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lucid Diagnostics Inc. Dividends, Buybacks & Capital Allocation
LUCD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lucid Diagnostics Inc. (CIK: 0001799011)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LUCD
What is the AI rating for LUCD?
Lucid Diagnostics Inc. (LUCD) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LUCD's key strengths?
Claude: Positive revenue growth of 8.3% YoY indicates market traction. Holds $34.7M in cash providing near-term operational runway. ChatGPT: Cash balance (~$34.7M) provides short-term liquidity runway. Low capex needs support an asset-light model.
What are the risks of investing in LUCD?
Claude: Approximately 9-month cash runway at -$46.7M annual operating cash burn rate; existential liquidity risk. Gross margin of 8% is catastrophically low for medical devices; indicates fundamental business model challenges. ChatGPT: Severe cash burn and FCF deeply negative, raising dilution/going-concern risk. High leverage (Debt/Equity 2.22x) with negative interest coverage.
What is LUCD's revenue and growth?
Lucid Diagnostics Inc. reported revenue of $4.7M.
Does LUCD pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
Where can I find LUCD SEC filings?
Official SEC filings for Lucid Diagnostics Inc. (CIK: 0001799011) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LUCD's EPS?
Lucid Diagnostics Inc. has a diluted EPS of $-0.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LUCD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lucid Diagnostics Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LUCD stock overvalued or undervalued?
Valuation metrics for LUCD: ROE of -530.4% (sector avg: 15%), net margin of -1,232.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LUCD stock in 2026?
Our dual AI analysis gives Lucid Diagnostics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LUCD's free cash flow?
Lucid Diagnostics Inc.'s operating cash flow is $-46.5M, with capital expenditures of $197.0K. FCF margin is -992.0%.
How does LUCD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,232.7% (avg: 12%), ROE -530.4% (avg: 15%), current ratio 1.31 (avg: 2).
Is Lucid Diagnostics Inc. carrying too much debt?
LUCD has a debt-to-equity ratio of 2.22x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.31 suggests adequate short-term liquidity.